10X Genomics (TXG) 44th Annual J.P. Morgan Healthcare Conference summary

Financial performance and recent results

• Achieved $599 million in 2025 revenue and $166 million in Q4, surpassing guidance, with year-end cash balance exceeding $520 million and over $100 million cash growth from 2024.

• Q4 growth was driven by both instruments and consumables, with CapEx growing nearly 30% sequentially and Chromium consumables reactions up more than 20%.

• Chromium instrument placements reached over 6,400 cumulatively, with 1,500 spatial instruments sold by end of 2025; instrument demand remains challenged by tight capital budgets.

• Spatial consumables and the Flex assay saw strong momentum, with Flex becoming the most popular assay by volume last quarter.

• Plan to reinstate full-year guidance during the Q4 call, barring unforeseen circumstances.

Product innovation and platform development

• Operates three category-defining platforms, launching over 35 major products in the last decade and maintaining the largest ecosystem of users and publications.

• Chromium leads in single cell analysis, with Flex assay offering sensitivity, flexibility, and cost-effectiveness.

• Spatial platforms Visium and Xenium enable comprehensive molecular, cellular, and tissue analysis; Xenium is now the primary growth engine in spatial.

• Multi-omics capabilities introduced with Xenium RNA and protein panel, receiving strong initial feedback for practical, scalable workflows.

• Acquired Scale Biosciences to enhance experiment scale and integrate new technologies into the Chromium portfolio.

AI and virtual cell initiatives

• Integrates large-scale biological data with AI models to accelerate understanding and medicine development.

• Supports development of virtual cell foundation models, collaborating with leading academic and industry partners.

• Provides massive, high-quality datasets essential for training AI models in therapeutic discovery.

• Announced partnership with Cancer Research Institute to build a Discovery Engine dataset for immunotherapy and a high-resolution immune atlas.

• AI partnerships, such as with Anthropic, aim to address data analysis bottlenecks and further integrate AI into research workflows.